SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.

Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.
PLoS Genetics (Impact Factor: 8.52). 09/2010; 6(9). DOI: 10.1371/journal.pgen.1001101
Source: PubMed

ABSTRACT Alzheimer's Disease (AD) is a complex and multifactorial disease. While large genome-wide association studies have had some success in identifying novel genetic risk factors for AD, case-control studies are less likely to uncover genetic factors that influence progression of disease. An alternative approach to identifying genetic risk for AD is the use of quantitative traits or endophenotypes. The use of endophenotypes has proven to be an effective strategy, implicating genetic risk factors in several diseases, including anemia, osteoporosis and heart disease. In this study we identify a genetic factor associated with the rate of decline in AD patients and present a methodology for identification of other such factors. We have used an established biomarker for AD, cerebrospinal fluid (CSF) tau phosphorylated at threonine 181 (ptau(181)) levels as an endophenotype for AD, identifying a SNP, rs1868402, in the gene encoding the regulatory sub-unit of protein phosphatase B, associated with CSF ptau(181) levels in two independent CSF series (P(combined) = 1.17 x 10(-05)). We show no association of rs1868402 with risk for AD or age at onset, but detected a very significant association with rate of progression of disease that is consistent in two independent series (P(combined) = 1.17 x 10(-05)). Our analyses suggest that genetic variants associated with CSF ptau(181) levels may have a greater impact on rate of progression, while genetic variants such as APOE4, that are associated with CSF Aβ(42) levels influence risk and onset but not the rate of progression. Our results also suggest that drugs that inhibit or decrease tau phosphorylation may slow cognitive decline in individuals with very mild dementia or delay the appearance of memory problems in elderly individuals with low CSF Aβ(42) levels. Finally, we believe genome-wide association studies of CSF tau/ptau(181) levels should identify novel genetic variants which will likely influence rate of progression of AD.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Apolipoprotein E (APOE) is the most statistically significant genetic risk factor for late-onset Alzheimer disease (LOAD). The linkage disequilibrium pattern around the APOE gene has made it difficult to determine whether all the association signal is derived from APOE or whether there is an independent signal from a nearby gene. To attempt to replicate a recently reported association of APOE 3-TOMM40 haplotypes with risk and age at onset. We used standard techniques to genotype several polymorphisms in the APOE-TOMM40 region in a large case-control series, in a series with cerebrospinal fluid biomarker data, and in brain tissue. Alzheimer's Disease Research Center. Research volunteers who were cognitively normal or had Alzheimer disease. Disease status and age at onset. We did not replicate the previously reported association of the polyT polymorphism (rs10524523) with risk and age at onset. We found a significant association between rs10524523 and risk of LOAD in APOE 33 homozygotes but in the opposite direction as the previously reported association (the very long allele was underrepresented in cases vs controls in this study (P = .004]). We found no association between rs10524523 and cerebrospinal fluid tau or β-amyloid 42 levels or TOMM40 or APOE gene expression. Although we did not replicate the earlier association between the APOE 3-TOMM40 haplotypes and age at onset, we observed that the polyT polymorphism is associated with risk of LOAD in APOE 33 homozygotes in a large case-control series but in the opposite direction as in the previous study.
    Archives of neurology 08/2011; 68(8):1013-9. · 7.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tauopathies are a class of neurodegenerative diseases marked by intracellular aggregates of hyperphosphorylated tau. These diseases may occur by sporadic mechanisms in which genetic variants represent risk factors for disease, as is the case in Alzheimer's disease (AD). In AD, cerebrospinal fluid (CSF) levels of soluble tau/ptau181 are higher in cases compared to controls. A subset of frontotemporal dementia (FTD) cases occur by a familial mechanism in which MAPT, the gene that encodes tau, mutations are dominantly inherited. In symptomatic FTD patients expressing a MAPT mutation, CSF tau levels are slightly elevated but are significantly lower than in AD patients. We sought to model CSF tau changes by measuring extracellular tau in cultured cells. Full-length, monomeric extracellular total tau and ptau181 were detectable in human neuroblastoma cells expressing endogenous tau, in human non-neuronal cells over-expressing wild-type tau, and in mouse cortical neurons. Tau isoforms influence the rate of tau release, whereby the N-terminus (exons 2/3) and microtubule binding repeat length contribute to tau release from the cell. Compared with cells over-expressing wild-type tau, cells over-expressing FTD associated MAPT mutations produce significantly less extracellular total tau without altering intracellular total tau levels. This study demonstrates that cells actively release tau in the absence of disease or toxicity, and tau release is modified by changes in the tau protein that are associated with tauopathies.
    Journal of Biological Chemistry 10/2012; · 4.65 Impact Factor
  • Source
    Neurobiology of aging 01/2012; 33:1486.e9-15. · 5.94 Impact Factor

Full-text (2 Sources)

Available from
Jun 6, 2014